AbbVie said its two phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia (experiencing an acute exacerbation of psychotic ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie said that its Phase 2 trial investigating ...

FAILS TO MEET ENDPOINT: AbbVie’s two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial A clinical researcher in a lab examining a new biopharmaceutical product. Atogepant is an oral medication taken once daily to ...

Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...

NORTH CHICAGO - AbbVie (NYSE: ABBV), a prominent player in the biotechnology industry with annual revenue of $57.37 billion, announced today that its Phase 3 VERONA trial evaluating venetoclax in ...

AbbVie has launched its Produodopa for Parkinson’s in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the disease.

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive.